Next event: Vote in plenary scheduled 2023/05/09
Progress: Awaiting committee decision
Role | Committee | Rapporteur | Shadows |
---|---|---|---|
Lead | ENVI | CANFIN Pascal ( Renew) | CLUNE Deirdre ( EPP), COVASSI Beatrice ( S&D), EICKHOUT Bas ( Verts/ALE), SARDONE Silvia ( ID), VONDRA Alexandr ( ECR), VILLANUEVA RUIZ Idoia ( GUE/NGL) |
Lead committee dossier:
Legal Basis:
TFEU 114
Legal Basis:
TFEU 114Events
PURPOSE : to provide specific rules relating to medicinal products for human use intended to be placed on the market of Northern Ireland.
PROPOSED ACT: Regulation of the European Parliament and of the Council.
ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council.
BACKGROUND: the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union entered into force on 1 February 2020. The Protocol on Ireland/Northern Ireland forms an integral part of the Withdrawal Agreement.
The provisions of Union law listed in Annex 2 to the Protocol apply, under the conditions set out in that Annex, to and in the United Kingdom in respect of Northern Ireland. That list includes, but it is not limited to, Directive 2001/83/EC of the European Parliament and of the Council lays down the rules for medicinal products for human use and Regulation (EC) No 726/2004 of the European Parliament and of the Council lays down Union procedures for the authorisation of medicinal products for human use. Therefore, medicinal products placed on the market in Northern Ireland are required to comply with those provisions of Union law.
In order to take account of the specific situation of Northern Ireland, it is appropriate to adopt specific rules relating to the placing on the market of Northern Ireland of medicinal products for human use.
The UK and certain stakeholders based in the UK have raised concerns that the need for separate marketing authorisations for Great Britain and Northern Ireland in respect of novel medicines and the application of the Union unique identifier requirement for medicines subject to prescription impose unnecessary administrative burdens for medicines that are to be placed only on the Northern Ireland market and will not be made available in any Member State.
The Commission and the Government of the UK have thus reached a comprehensive set of joint solutions to address these concerns, while protecting the integrity of both the Union’s and the UK’s internal markets.
This proposal reflects these joint solutions.
CONTENT: the proposal provides that:
- new and innovative medicines lawfully placed on the market in Northern Ireland are to be only covered by a valid marketing authorisation issued by the UK according to the law of the UK. The placing on the market of these medicines will therefore not anymore be regulated by EU-wide authorisations granted by the Commission;
- the EU safety features that must be displayed on packs of medicines subject to prescription in the Union should not appear on packs of medicines made available to patients in Northern Ireland.
These solutions are accompanied by safeguards to ensure that all medicines placed on the market in Northern Ireland will not be made available in any Member State. These include labelling UK packs with a specific label: “ UK only ”, continuous monitoring by the UK competent authorities as well as the possibility for the Commission to unilaterally suspend the application of the new rules in case of UK non-compliance with its obligations.
The proposal empowers the Commission to adopt the necessary delegated acts for the suspension of specific rules if there is evidence that the UK does not take appropriate measures to tackle serious or repeated infringements of the specific rules. The act also provides for a number of safeguard mechanisms to ensure that the integrity of the Union’s internal market is protected.
Documents
Amendments | Dossier |
9 |
2023/0064(COD)
2023/04/12
ENVI
9 amendments...
Amendment 1 #
Proposal for a regulation Citation 1 Having regard to the Treaty on the Functioning of the European Union, and in particular Articles 114 and 168(4)(c) thereof,
Amendment 2 #
Proposal for a regulation Recital 8 The specific rules should include the prohibition to display the safety features referred to in Directive 2001/83/EC on the outer packaging or, where there is no outer packaging, on the immediate packaging of medicinal products for human use intended to be placed on the market in Northern Ireland, with the exception of the anti- tampering device measures set out in Directive 2011/62/EU which should remain in place. The specific rules should also include and the prohibition to place on the market in Northern Ireland new and innovative medicinal products that have been granted a marketing authorisation in accordance with Regulation (EC) No 726/2004. Furthermore, the specific rules should include certain labelling requirements for medicinal products for human use intended to be placed on the market in Northern Ireland. As a consequence, Commission Delegated Regulation (EU) 2016/1616 should not apply to medicinal products for human use intended to be placed on the market in Northern Ireland.
Amendment 3 #
Proposal for a regulation Recital 9 (9) In respect of new and innovative products, the competent authorities of the United Kingdom should be able to authorise the placing of these products on the market in Northern Ireland once certain conditions are fulfilled, including that the authorisation is granted in accordance with the law of the United Kingdom and that the products are placed on the market in Northern Ireland under the terms of the authorisation granted by the competent authorities of the United Kingdom, that these products comply with certain labelling requirements, and lastly that the written guarantees have been provided by the United Kingdom to the European Commission.
Amendment 4 #
Proposal for a regulation Article 3 – paragraph 2 The safety features referred to in Article 54, point (o) with the exception of the anti-tampering device measures, of Directive 2001/83/EC shall not appear on the outer packaging or, where there is no outer packaging, on the
Amendment 5 #
Proposal for a regulation Article 3 – paragraph 3 Where a medicinal product referred to in Article 1(1) of this Regulation bears the safety feature referred to in Article 54, point (o) with the exception of the anti- tampering device measures, of Directive 2001/83/EC, it shall be fully removed or covered.
Amendment 6 #
Proposal for a regulation Article 3 – paragraph 4 The qualified person referred to in Article 48 of Directive 2001/83/EC shall, in the case of medicinal products referred to in Article 1(1) of this Regulation, ensure that the safety features referred to in Article 54, point (o) with the exception of the anti- tampering device measures, of Directive 2001/83/EC have not been affixed on the packaging of the medicinal product.
Amendment 7 #
Proposal for a regulation Article 3 – paragraph 5 – point b (b) keep records in accordance with the last indent of Article 80, point (e), of Directive 2001/83/EC.
Amendment 8 #
Proposal for a regulation Article 14 – paragraph 2 It shall apply from 1 January 2025, provided that the United Kingdom has provided the written guarantees referred to in Article 8 and that the Commission has published prior to that date the Notice referred to in the fifth subparagraph.
Amendment 9 #
Proposal for a regulation Article 14 – paragraph 3 a (new) Within one month after reception of those written guarantees, the Commission shall provide a report to the European Parliament and the Council of its assessment thereof.
source: 745.507
|
History
(these mark the time of scraping, not the official date of the change)
committees/1 |
|
procedure/legal_basis/0 |
Rules of Procedure EP 40
|
forecasts/0 |
|
forecasts/0 |
|
docs/1 |
|
docs/0 |
|
docs/0 |
|
committees/0/shadows |
|
committees/0/rapporteur |
|
forecasts |
|
events/1 |
|
procedure/dossier_of_the_committee |
|
procedure/stage_reached |
Old
Preparatory phase in ParliamentNew
Awaiting committee decision |
events/0/summary |
|